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TO THE EDITOR
Molluscum contagiosum virus (MCV)
produces smooth, flesh-colored papules
with central umbilication. In HIV-
infected individuals, extensive and
recalcitrant MCV lesions are a thera-
peutic challenge. Meadows et al. (1997)
first described therapeutic success with
topical or intravenous cidofovir (CDV),
a nucleoside analog of deoxycytidine
monophosphate, for otherwise recalci-
trant MCV lesions in three AIDS
patients. Topical 1–3% CDV cream has
been highly efficacious in treating gene-
ralized MCV lesions, with successful
treatment of a boy with Wiskott–Aldrich
syndrome (Davies et al., 1999), two
HIV-infected children (Toro et al.,
2000), and two otherwise healthy chil-
dren (Zabawski and Cockerell, 1999).
Because MCV cannot be propagated
in tissue culture and does not infect
animals, overexpression of MCV DNA
polymerase is necessary to evaluate the
effects of CDV on viral DNA polymer-
ase activity. However, identifying a
successful overexpression system for
this enzyme has been difficult. Dorsky
and Crumpacker (1988) reported high
expression of herpes simplex virus-1
(HSV-1) DNA polymerase in E. coli,
but the recombinant protein was insolu-
ble and enzymatically inactive. Haffey
et al. (1988) successfully expressed
HSV-1 DNA polymerase in the yeast
Saccharomyces cerevisiae, but the ex-
tracts also contained the yeast a DNA
polymerase. McDonald and Traktman
(1994) found that vaccinia virus DNA
polymerase cannot be expressed in
E. coli due to extreme toxicity and
proteolysis or in S. cerevisiae due to
transcriptional termination within the
polymerase gene. To overcome these
technical issues, we selected an in vitro
transcription–translation system to ex-
press viral DNA polymerases, similar to
the successful expression systems for
HSV-1 DNA polymerase (Dorsky and
Crumpacker, 1988) and equine herpes-
virus 1 (Loregian et al., 2006).
We cloned the viral DNA polymer-
ase genes of MCV (MC39L), cowpox
virus (CPV) (CPXV75), and HSV-1
(UL30) into the T7 expression vector
pGEM-3Z (Promega, Madison, WI). Of
these,MC39L and CPXV75 are the most
closely related, with 53% identity and
72% similarity (Figure 1a). For MC39L,
a 3,159-bp AccIII–BstPI fragment span-
ning the complete MC39L from 12-bp
upstream of the ATG to 133-bp down-
stream of the TAG was inserted into
pGEM-3Z. For CPXV75, a PCR product
from 6-bp upstream of the ATG to
381 bp 50 of CPXV75 was generated
using primers 50-GGTACCTAGAAATG
GATGTTCGGTGC-30 (KpnI site, under-
lined) and 50-TCGTCCAACGAGTAACA
TCC-30, shortened to 362bp by KpnI–
EcoRV digestion, and cloned into the
KpnI–BamHI sites of pGEM-3Z along
with a 4,591-bp EcoRV–BamHI fragment
containing 2,664bp 30 of CPXV75. For
UL30, 524bp 50 of UL30 was amplified
with primers 50-GAATTCATGTTTTCCG
GTGGCGGCGG-30 (EcoRI site, under-
lined) and 50-ATGGCGTCCATAAACCG
CGC-30, shortened to 482bp by EcoRI–-
SphI digestion, and inserted into the
EcoRI–SphI site of pGEM-3Z along with
a 3,760-bp SphI fragment containing
3,227bp 30 of UL-30.
The cloned DNA polymerase genes
were transcribed with T7 RNA
polymerase and translated in rabbit
reticulocyte lysates (Promega). Poly-
merases synthesized in the presence of
[35S]methionine were visualized by
electrophoresis (Figure 1b). DNA poly-
merase assays were performed in 100 ml
volumes containing 10 mg of activated
calf thymus DNA, 100mM ammonium
sulfate, 50mM Tris–hydrochloride (pH
8.0), 50 mg of BSA, 0.5mM dithiothre-
itol, 7.5mM MgCl2, 5 mM each of dCTP,
dGTP, and dTTP, and 2.5mCi of [32P]
dATP (3,000CimM1) as described
(Dorsky and Crumpacker, 1988). The
incorporation of [32P]dATP by the pro-
grammed reticulocyte lysates increased
linearly with time up to 20minutes
(Figure 2). In contrast, the endogenous
polymerase activity of the control
reticulocyte lysates without mRNA re-
mained near the filter background level
(data not shown).
Once taken up by cells, CDV is
converted to a diphosphate (CDVpp)
and acts as a competitive inhibitor
of viral DNA polymerases. The effects
of CDVpp (Trilink Biotechnologies,
San Diego, CA) on viral DNA poly-
merases were examined using 30 ml
of reticulocyte lysates programmed
with 8 mg of transcripts for each viral
DNA polymerase gene. MCV, CPV, and
Abbreviations: CDV, cidofovir; CDVpp, cidofovir diphosphate; CPV, cowpox virus; HSV, herpes simplex
virus; MCV, molluscum contagiosum virus
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HSV-1 DNA polymerase activities were
completely inhibited by 50 mM CDVpp
(Figure 2a–c). These observations are
consistent with the plaque reduction
assay results, showing that the mini-
mum inhibitory concentration required
to inhibit virus-induced cytopathogeni-
city by 50% (IC50) is 31–62 and
12.7–31.7 mM for CPV and HSV-1,
respectively (Safrin et al., 1997). Since
the maximum plasma concentration
(Cmax) of CDV is 26–72 mM (Hitchcock
et al., 1996), intravenous administration
of CDV would inhibit these viruses. In
contrast, CDVpp did not inhibit E. coli
DNA polymerase activity elicited by
Klenow fragment (Figure 2d), suggest-
ing that CDV derives its specificity from
a higher affinity for viral DNA poly-
merases than for bacterial or human
DNA polymerases in cell culture (Safrin
et al., 1997).
Unlike acyclovir and other nucleo-
side analogs, CDV is not dependent on
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Figure 1. Primary structure comparisons and expression of viral DNA polymerase genes. (a) Alignment of the deduced amino-acid sequences of MC39L
(GenBank accession number U60315), CPXV75 (DQ066528), and HSV-1 UL30 (AB231455). Boldface letters indicate identical amino acids. Gray
boxes highlight identical and conserved amino acids. Dots indicate gaps in the sequence to allow optimal alignment. Numbers on the right indicate the
amino-acid position. (b) Rabbit reticulocyte lysates were programmed with mRNA in the presence of [35S]methionine and then visualized by SDS-PAGE.
The apparent molecular weights of the three viral DNA polymerases were 116 kDa (MCV and CPV) and 140 kDa (HSV-1), consistent with the predicted
sizes and corresponding to the sizes of expressed or purified polypeptides in previous studies (Dorsky and Crumpacker, 1988; Haffey et al., 1988;
McDonald and Traktman, 1994). The luciferase gene was expressed as a positive control. The positions and masses of protein markers are on the left.
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Figure 2. CDVpp inhibits in vitro translated DNA polymerase. DNA polymerase inhibition assays were performed as described in the text at the noted
CDVpp concentrations. One representative assay out of three is shown for each viral DNA polymerase. The rabbit reticulocyte lysates were programmed
with (a) MC39L, (b) CPXV75, and (c) HSV-1 UL30 mRNA and used for DNA polymerase assays. (d) For E. coli DNA polymerase assay, Klenow fragment
(Takara Bio, Shiga, Japan) was used instead of programmed lysates.
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phosphorylation by a virally encoded
thymidine kinase to exert its antiviral
effect. This mechanism of action would
be advantageous as a therapy for MCV,
which does not possess a functional
thymidine kinase (Gubser et al., 2004).
In fact, acyclovir and foscarnet are
ineffective against CPV because the
virally encoded thymidine kinase does
not catalyze acyclovir or foscarnet (Baker
et al., 2003). In contrast, several studies
have unequivocally shown that CDV is a
highly effective prophylactic and thera-
peutic drug for lethal CPV infection in
mice (Neyts and De Clercq, 2003).
There is increasing interest in effec-
tive antiviral agents because of several
concerns: increasing risk of bioterro-
rism with variola virus as a biologic
weapon, recent outbreak of monkeypox
disease in humans, occasional orf
(sheep pox) infections, and smallpox
vaccination complications, such as
vaccinia gangrenosa and eczema vac-
cinatum (Neyts and De Clercq, 2003).
CDV is one of the most promising
antiviral agents with high efficacy
against the poxvirus family. In a case
of orf, the ecthyma infectiosum lesion
completely disappeared following topi-
cal application of 1% CDV that other-
wise would have led to amputation of
the affected finger (Geerinck et al.,
2001). In another study, antiviral treat-
ment with CDV was more effective than
smallpox vaccination after lethal infec-
tion of monkeys with monkeypox
(Stittelaar et al., 2006). We showed for
the first time that 20–50 mM of CDVpp
inhibited MCV DNA polymerase acti-
vity, providing biochemical support for
CDV as a treatment for MCV lesions.
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TO THE EDITOR
Limited information has been reported
concerning the effects of immune re-
sponses, especially Th2 type, on barrier
dysfunction in vivo. A recent study
reported that IL-4, a Th2 cytokine,
suppresses the enhancement of cera-
mide synthesis and cutaneous per-
meability barrier function induced by
tumor necrosis factor-a and IFN-g in
human epidermal sheets or in the living
skin equivalent, which is a model of
reconstructed skin in vitro. In addition,
IL-4 blocks the recovery of barrier
function and enhancement of ceramide
synthesis after barrier disruption by
acetone treatment in living skin equiva-
lent (Hatano et al., 2005, 2007). How-
ever, living skin equivalent seems
inadequate to observe cutaneous per-
meability barrier function, since the
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